The effect of carboxylesterase 1 (CES1) polymorphisms on the pharmacokinetics of prodrugs in humans

本研究旨在探讨前药的药代动力学是否受到羧酸酯酶（CES） 1A遗传多态性的影响。奥司他韦代谢的个体差异不能用CES1A遗传多态性来解释。然而，在总共30名受试者中，有一名受试者是一个异常值，奥司他韦的auc高出约10倍。CES1代谢个体差异的原因还有待进一步研究。

This study was designed to examine whether the pharmacokinetics of prodrug is affected by carboxylesterase (CES) 1A genetic polymorphisms. The individual differences in the metabolism of oseltamivir are not explained by the CES1A genetic polymorphisms. However, one subject, out of a total number of 30, was an outlier with about a10-fold higherAUC for oseltamivir. Further studies are required to reveal the cause of the individual differences in CES1 metabolism.